
|Videos|August 26, 2021
Role of First Generation FLT3 Inhibitors in AML
Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar, for Retinal Diseases
2
FDA Approves First Oral GLP-1 for Weight Management
3
Achieving Optimal LDL-C Helps Prevent Neoatherosclerosis, Late Stent Failure in Patients With STEMI
4
Orforglipron Shows Strong Weight Maintenance in Phase 3 ATTAIN-MAINTAIN Trial
5







































































































































































































